{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:36:05Z","timestamp":1784644565332,"version":"3.55.0"},"reference-count":27,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2023.0219","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:01:16Z","timestamp":1699966876000},"source":"Crossref","is-referenced-by-count":9,"title":["Shared decision making, diagnostic evaluation, and pharmacotherapy in type 2 diabetes"],"prefix":"10.3238","author":[{"given":"Christina","family":"Brockamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Landgraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich Alfons","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"M\u00fcller-Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Petrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Til","family":"Uebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2023,11,24]]},"reference":[{"key":"10.3238\/arztebl.m2023.0219_ref1","unstructured":"Heidemann C, Scheidt-Nave C, Beyer A-K, et al.: Gesundheitliche Lage von Erwachsenen in Deutschland \u2013 Ergebnisse zu ausgew\u00e4hlten Indikatoren der Studie GEDA 2019\/2020-EHIS. J Health Monit 2021; 6: 3\u201327."},{"key":"10.3238\/arztebl.m2023.0219_ref2","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale VersorgungsLeitlinie Typ-2-Diabetes \u2013 Langfassung, Version 3.0. www.doi.org\/10.6101\/AZQ\/000503 (last accessed on 21 April 2023)."},{"key":"10.3238\/arztebl.m2023.0219_ref3","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) \u2013 St\u00e4ndige Kommission Leitlinien: AWMF-Regelwerk Leitlinien: Version 2.0. www.awmf.org\/leitlinien\/awmf-regelwerk.html (last accessed on 22 March 2021)."},{"key":"10.3238\/arztebl.m2023.0219_ref4","doi-asserted-by":"crossref","unstructured":"Guyatt G, Oxman AD, Akl EA, et al.: GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383\u201394.","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"10.3238\/arztebl.m2023.0219_ref5","doi-asserted-by":"crossref","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, et al.: GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401\u20136.","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"10.3238\/arztebl.m2023.0219_ref6","doi-asserted-by":"crossref","unstructured":"Andrews J, Guyatt G, Oxman AD, et al.: GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013; 66: 719\u201325.","DOI":"10.1016\/j.jclinepi.2012.03.013"},{"key":"10.3238\/arztebl.m2023.0219_ref7","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale VersorgungsLeitlinie Typ-2-Diabetes \u2013 Leitlinienreport, 2. Auflage. Version 1. http:\/\/doi.org\/10.6101\/AZQ\/000476 (last accessed on 25 March 2021)."},{"key":"10.3238\/arztebl.m2023.0219_ref8","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale VersorgungsLeitlinie Typ-2-Diabetes \u2013 Leitlinienreport. Version 3.0. http:\/\/doi.org\/10.6101\/AZQ\/000500 (last accessed on 15 May 2023)."},{"key":"10.3238\/arztebl.m2023.0219_ref9","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG): Nutzenbewertung einer langfristigen, normnahen Blutzuckersenkung bei Patienten mit Diabetes mellitus Typ 2. Rapid Report. Auftrag A05\u201307. Version 1.0. www.iqwig.de\/download\/A05-07_Rapid-Report_Normnahe-Blutzuckersenkung-bei-Diabetes-mellitus-Typ-2.pdf (last accessed on 2 October 2020)."},{"key":"10.3238\/arztebl.m2023.0219_ref10","doi-asserted-by":"crossref","unstructured":"Petrak F, Meier JJ, Albus C, et al.: Motivation und Diabetes \u2013 Zeit f\u00fcr einen Paradigmenwechsel? \u2013 Ein Positionspapier. Diabet Stoffw 2019; 14: 193\u2013203.","DOI":"10.1055\/a-0868-7758"},{"key":"10.3238\/arztebl.m2023.0219_ref11","doi-asserted-by":"crossref","unstructured":"Peer N, Balakrishna Y, Durao S: Screening for type 2 diabetes mellitus. Cochrane Database Syst Rev 2020; 5: CD005266.","DOI":"10.1002\/14651858.CD005266.pub2"},{"key":"10.3238\/arztebl.m2023.0219_ref12","unstructured":"Agency for Healthcare Research and Quality: Screening for prediabetes and type 2 diabetes mellitus: an evidence review for the U.S. Preventive Services Task Force. AHRQ Publication No. 21-05276-EF-1. August 2021. www.uspreventiveservicestaskforce.org\/home\/getfilebytoken\/fsWsshejkRXPN5CWy7CPRM (last accessed on 13 May 2022)."},{"key":"10.3238\/arztebl.m2023.0219_ref13","doi-asserted-by":"crossref","unstructured":"Hemmingsen B, Gimenez-Perez G, Mauricio D, Roqu\u00e9 I Figuls M, Metzendorf M-I, Richter B: Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev 2017; 12: CD003054.","DOI":"10.1002\/14651858.CD003054.pub4"},{"key":"10.3238\/arztebl.m2023.0219_ref14","doi-asserted-by":"crossref","unstructured":"Richter B, Hemmingsen B, Metzendorf M-I, Takwoingi Y: Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia (Review). Cochrane Database Syst Rev 2018; 10: CD012661.","DOI":"10.1002\/14651858.CD012661.pub2"},{"key":"10.3238\/arztebl.m2023.0219_ref15","doi-asserted-by":"crossref","unstructured":"Roth J, M\u00fcller N, Lehmann T, Heinemann L, Wolf G, M\u00fcller UA: HbA1c and age in non-diabetic subjects: an ignored association? Exp Clin Endocrinol Diabetes 2016; 124: 637\u201342.","DOI":"10.1055\/s-0042-105440"},{"key":"10.3238\/arztebl.m2023.0219_ref16","doi-asserted-by":"crossref","unstructured":"Masuch A, Friedrich N, Roth J, Nauck M, M\u00fcller UA, Petersmann A: Preventing misdiagnosis of diabetes in the elderly: age-dependent HbA1c reference intervals derived from two population-based study cohorts. BMC Endocr Disord 2019; 19(1): 20.","DOI":"10.1186\/s12902-019-0338-7"},{"key":"10.3238\/arztebl.m2023.0219_ref17","doi-asserted-by":"crossref","unstructured":"Landgraf R, Heinemann L, Schleicher E. et al. Definition, Klassifikation, Diagnostik und Differenzialdiagnostik des Diabetes mellitus: Update 2022. Diabetol Stoffwechs 2022;17 (Suppl 2): S98\u2013S110.","DOI":"10.1055\/a-1789-5615"},{"key":"10.3238\/arztebl.m2023.0219_ref18","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (ADA): 2. classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 2021; 44: S15\u2013S33.","DOI":"10.2337\/dc21-S002"},{"key":"10.3238\/arztebl.m2023.0219_ref19","unstructured":"International Diabetes Federation (IDF): IDF Diabetes Atlas 2019. 9th ed. Br\u00fcssel: IDF 2019."},{"key":"10.3238\/arztebl.m2023.0219_ref20","unstructured":"World Health Organization (WHO): global report on diabetes. Genf: WHO 2016."},{"key":"10.3238\/arztebl.m2023.0219_ref21","doi-asserted-by":"crossref","unstructured":"Andersen ST, Witte DR, Dalsgaard EM, et al.: Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark. Diabetes Care 2018; 41: 1068\u201375.","DOI":"10.2337\/dc17-2062"},{"key":"10.3238\/arztebl.m2023.0219_ref22","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes \u2013 Langfassung, 1. Auflage. Version 4. http:\/\/doi.org\/10.6101\/AZQ\/000213 (last accessed on 12 January 2017)."},{"key":"10.3238\/arztebl.m2023.0219_ref23","doi-asserted-by":"crossref","unstructured":"Kanie T, Mizuno A, Takaoka Y, et al.: Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 2021; 10: CD013650.","DOI":"10.1002\/14651858.CD013650.pub2"},{"key":"10.3238\/arztebl.m2023.0219_ref24","doi-asserted-by":"crossref","unstructured":"Nathan DM, Lachin JM, Bebu I, et al.: Glycemia reduction in type 2 diabetes\u2014microvascular and cardiovascular outcomes. N Engl J Med 2022; 387: 1075\u201388.","DOI":"10.1056\/NEJMoa2200436"},{"key":"10.3238\/arztebl.m2023.0219_ref25","doi-asserted-by":"crossref","unstructured":"GRADE Study Research Group, Nathan DM, Lachin JM, Balasubramanyam A, et al.: Glycemia reduction in type 2 diabetes\u2014glycemic outcomes. N Engl J Med 2022; 387: 1063\u201374.","DOI":"10.1056\/NEJMoa2200433"},{"key":"10.3238\/arztebl.m2023.0219_ref26","doi-asserted-by":"crossref","unstructured":"Kaur G, Lakshmi PVM, Rastogi A, et al.: Diagnostic accuracy of tests for type 2 diabetes and prediabetes: a systematic review and meta-analysis. PLoS One 2020; 15: e0242415.","DOI":"10.1371\/journal.pone.0242415"},{"key":"10.3238\/arztebl.m2023.0219_ref27","doi-asserted-by":"crossref","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al.: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323\u201334.","DOI":"10.1056\/NEJMoa1515920"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T13:01:44Z","timestamp":1699966904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,24]]},"references-count":27,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2023.0219","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,24]]}}}